High dose of d-chiro-inositol improves oocyte quality in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial.

Nicolas Mendoza, Maria Isabel Galan, Cristina Molina, Raquel Mendoza-Tesarik, Cristina Conde, Maryna Mazheika, Maria Paz Diaz-Ropero, Juristo Fonolla, Jan Tesarik, Monica Olivares

Journal: Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 2021;36(5):398-401

PMID: 31657275

Abstract

The aim of this study was to evaluate the effect of two doses of d-chiro-inositol (DCI) in combination with Myo-inositol (MYO) on the oocyte quality (OQ) of women with polycystic ovarian syndrome (PCOS) undergoing intracytoplasmic sperm injection (ICSI). This was a controlled, randomized, double-blind, parallel group study on 172 oocytes from 11 women. The study compared the effect of two MYO-DCI formulations given over 12 weeks on OQ. Five women received 550 mg of MYO + 300 mg of DCI daily (high DCI content group), while 6 women were given a daily dose of 550 mg of MYO with the only 27.6 mg of DCI (low DCI content group). According to a multivariate analysis using linear mixed effect models, high doses of DCI have a positive influence on the quality of the cytoplasm of the oocyte ( = 1.631,  = 7.347, d.f. = 1,  = .00672). Zona pellucida, plasma membrane, cytoplasm, and sperm reception have also been improved with any combination of MYO/DCI by decreasing testosterone or improving insulin sensitivity, regardless of age and body mass index. The combination of MYO with high doses of DCI improved oocyte cytoplasm quality in women with PCOS undergoing ICSI.

Address: Department of Obstetrics and Gynecology, University of Granada, Granada, Spain.; Clinica MARGEN, Granada, Spain.; Biosearch Life, Granada, Spain.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.